Literature DB >> 6709313

Diabetic retinopathy. Assessment of severity and progression.

B E Klein, M D Davis, P Segal, J A Long, W A Harris, G A Haug, Y L Magli, S Syrjala.   

Abstract

This study describes a classification of overall retinopathy severity based on the presence and severity of lesions graded in the Airlie House classification of diabetic retinopathy, and demonstrates its use in assessing progression of retinopathy over a 6-year period in a group of insulin-taking patients. One hundred and ninety-one insulin-taking patients with diabetes of at least 5 years' duration were identified from their doctors' records in 1970-1971. Patients were seen again in 1972-1973 and 1976-1977. Stereoscopic color fundus photographs of 7 fields in each eye were taken at each visit. All photos were graded using a modification of the Airlie House classification, which specified 6 levels of retinopathy for a given eye; when both eyes are considered an 11-step grading scheme results. Of all patients seen at the 2-year visit whose retinopathy was at risk of progressing, 41.2% showed progression of one level or more on the scale, 19.2% progression of two or more levels. At the 6-year examination comparable rates were 75.0% and 58.4%. Of patients whose retinopathy was level 4 in each eye (nonproliferative retinopathy of "moderate" severity) at the baseline visit, 13/21 (72%) had progressed to proliferative retinopathy in at least one eye at the 6-year examination. The classification scheme proposed appears useful for characterizing overall retinopathy severity of patients on the basis of gradings of fundus photographs. The data presented may be of help in planning trials of treatment aimed at slowing the development or progression of retinopathy.

Entities:  

Mesh:

Year:  1984        PMID: 6709313     DOI: 10.1016/s0161-6420(84)34374-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  49 in total

1.  Retinopathy in a population-based study.

Authors:  R Klein
Journal:  Trans Am Ophthalmol Soc       Date:  1992

2.  Objective autorefraction in posterior chamber pseudophakia.

Authors:  P S Raj; T Akingbehin; A M Levy
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

3.  Does vitreous fluorophotometry reflect severity of early diabetic retinopathy?

Authors:  W E Plehwe; M A Sleightholm; E M Kohner
Journal:  Br J Ophthalmol       Date:  1989-04       Impact factor: 4.638

4.  The Hermann-Hering grid illusion demonstrates disruption of lateral inhibition processing in diabetes mellitus.

Authors:  Nigel P Davies; Antony B Morland
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

5.  Clinical evaluation of automated refraction in anterior chamber pseudophakia.

Authors:  P Sunder Raj; J R Villada; K Myint; A E Lewis; T Akingbehin
Journal:  Br J Ophthalmol       Date:  1991-01       Impact factor: 4.638

Review 6.  Does pregnancy accelerate the rate of progression of diabetic retinopathy?

Authors:  Bhavna P Sheth
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

7.  Visual evoked potentials after photostress in insulin-dependent diabetic patients with or without retinopathy.

Authors:  V Parisi; L Uccioli; G Monticone; L Parisi; G Menzinger; M G Bucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

8.  The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study.

Authors:  Ronald Klein; Barbara E K Klein; Scot E Moss; Tien Y Wong
Journal:  Trans Am Ophthalmol Soc       Date:  2006

9.  Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy.

Authors:  M A Di Leo; S Caputo; B Falsini; V Porciatti; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

10.  Spatial visual filtering in diabetes mellitus.

Authors:  Nigel Philip Davies; Antony Bryan Morland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.